Recombinant Proteins for the Treatment of Intracerebral Hemorrhage



Intracerebral hemorrhage (ICH) is a devastating form of stroke, with the highest mortality of all stroke subtypes.  Rapid accumulation of blood and immune cells  result in oxidative stress, inflammation, and the accumulation of toxic hemolytic products at the site of the stroke, leading to significant injury to the brain.  There are no effective treatments currently available for ICH. 


Technology Description

Lactoferrin is an endogenous glycoprotein with anti-microbial and immunoregulatory functions, with the potential to curtail the inflammatory response and promote repair. However, endogenous lactoferrin has limited therapeutic potential due to its short half-life in the blood and its difficulty penetrating the blood-brain barrier.  Researchers at UTHealth have optimized lactoferrin by creating a novel fusion protein that has been demonstrated to combat multiple aspects of ICH pathogenesis. 


Development Status

This technology has been tested for safety and efficacy in mice, large animal studies are ongoing. 


Intellectual Property Status

PCT application filed

Technology is available for licensing


Inventors: Jaroslaw Aronowski, Marian Kruzel

Related publications:

Nat Commun. 2017 Sep 19;8(1):602. doi: 10.1038/s41467-017-00770-7.


Patent Information:

The preceding is intended to be a non-confidential and limited description of a novel technology created at the University of Texas Health Science Center at Houston (UTHealth). This promotional material is not comprehensive in scope and should not replace company’s diligence in a thorough evaluation of the technology. Please contact the Office of Technology Management for more information regarding this technology.
For Information, Contact:
Hannah Nelson
Senior Technology License Associate
University of Texas Health Science Center At Houston
© 2022. All Rights Reserved. Powered by Inteum